Most people on a GLP-1 worry less about whether it works and more about whether they can tolerate it. Nausea, in particular, drives a lot of the search for the "gentlest" option. The honest answer is that all GLP-1 medications share a similar side effect pattern, the differences are real but modest, and how you start the medication matters as much as which one you pick. Here is a straight comparison.
Which GLP-1 has the fewest side effects?
Answer-first: there is no single winner. Among currently marketed drugs, the lowest nausea rates on the labels belong to the type 2 diabetes doses of dulaglutide and tirzepatide (Mounjaro, 12 to 18%), while every weight-management label sits higher: Zepbound 25 to 29%, Foundayo 26 to 35%, Saxenda 39.3%, Wegovy 44%. Correction, September 2026: an earlier version of this page recommended lixisenatide and exenatide; lixisenatide (Adlyxin) left the US market on January 1, 2023 and Byetta and Bydureon BCise (exenatide) were discontinued in October 2024, so both have been removed.
Across published trials, GLP-1 tolerability tracks dose and potency. The weight-management doses of semaglutide and tirzepatide produce more weight loss and more gastrointestinal effects than the lower diabetes doses of the same molecules, and a 2025 network meta-analysis of 48 randomized trials in type 2 diabetes (27,729 participants) ranked dulaglutide lowest for nausea and vomiting and tirzepatide highest for nausea and diarrhea. So "fewest side effects" and "most weight loss" rarely point to the same drug. Percentages from different trials are not exact head-to-head comparisons; the label table below is the most consistent yardstick available.
Which GLP-1 causes the least nausea?
Answer-first: at type 2 diabetes doses, dulaglutide ranked lowest for nausea in the 2025 network meta-analysis (about 10%, versus about 25% for tirzepatide). At weight-management doses the picture flips for liraglutide: the Saxenda label (revised 02/2026) reports nausea in 39.3% of participants, higher than Zepbound's 25 to 29%. Correction, September 2026: an earlier version ranked liraglutide and lixisenatide as low-nausea options; liraglutide's weight-loss dose is not, and lixisenatide is no longer sold in the US.
Nausea is the most common GLP-1 side effect and is dose-dependent. It tends to peak in the first weeks after starting or increasing a dose, then ease as the body adapts. On the 2026 labels, nausea runs from 12% (Mounjaro 5 mg) to 44% (Wegovy 2.4 mg injection). Because each trial measured nausea against its own placebo group, treat cross-drug comparisons as approximate; the reliable pattern is that potency tracks with nausea and slow titration reduces it.
Why does potency affect tolerability?
Answer-first: the same mechanism that drives appetite suppression and weight loss also drives the gastrointestinal effects.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →GLP-1 receptor agonists slow gastric emptying and act on appetite centers in the brain. Those actions reduce food intake, and they also produce nausea, fullness, and sometimes vomiting or diarrhea. Tirzepatide adds GIP receptor activity to the GLP-1 effect, giving strong results but a broad effect profile. There is no GLP-1 that delivers major weight loss with no gastrointestinal effect, because the benefit and the side effects come from overlapping pathways.
How can you reduce GLP-1 side effects?
Answer-first: slow dose escalation and a few eating habits do more for tolerability than switching brands.
The single most effective tolerability tool is following the titration schedule and not rushing to a higher dose. Eating smaller meals, stopping when full, limiting greasy or very rich foods in the early weeks, and staying hydrated all help. Nausea that appears after a dose increase usually settles within a week or two. Severe or persistent vomiting, dehydration, or signs of pancreatitis warrant prompt medical attention rather than pushing through.
Comparison table
Correction, September 2026: the earlier table used qualitative terms ("lower to moderate") and included two drugs no longer sold in the US. It has been replaced with the adverse-reaction percentages printed on each current label, seen September 5, 2026. Placebo rates are in parentheses.
| Medication (label revision) | Dosing | Nausea | Diarrhea | Vomiting | Constipation | Notes |
|---|---|---|---|---|---|---|
| Mounjaro, tirzepatide for type 2 diabetes (08/2026) | Weekly injection, 5/10/15 mg | 12/15/18% (4%) | 12/13/17% (9%) | 5/5/9% (2%) | 6/6/7% (1%) | Diabetes trials; discontinuation for GI events 3.0/5.4/6.6% vs 0.4% |
| Zepbound, tirzepatide for weight management (08/2026) | Weekly injection, 5/10/15 mg | 25/29/28% (8%) | 19/21/23% (8%) | 8/11/13% (2%) | 17/14/11% (5%) | Highest weight loss of the approved drugs; AE discontinuation in Study 1 4.3/7.1/6.2% vs 2.6% |
| Foundayo, orforglipron (07/2026) | Once-daily tablet, 5.5/9/17.2 mg | 26/34/35% (10%) | 21/23/25% (11%) | 13/21/24% (4%) | 20/27/24% (9%) | New oral option approved 2026; GI events overall 60 to 69% vs 37% |
| Saxenda, liraglutide 3 mg (02/2026) | Daily injection | 39.3% (13.8%) | 20.9% (9.9%) | 15.7% (3.9%) | 19.4% (8.5%) | Long track record; daily injection |
| Wegovy, semaglutide 2.4 mg injection (06/2026) | Weekly injection; a daily tablet (25 mg maintenance) is also approved | 44% (16%) | 30% (16%) | 24% | 24% | Strong weight loss; titrate slowly |
Dulaglutide (Trulicity) is approved for type 2 diabetes, not weight management, and is not tabulated here; the 2025 network meta-analysis places its nausea rate around 10% at diabetes doses. Lixisenatide (Adlyxin) has not been sold in the US since January 1, 2023, and Byetta and Bydureon BCise (exenatide) were discontinued in October 2024.
How does compounded semaglutide or tirzepatide fit in?
Answer-first: compounded versions are clinician-prescribed alternatives to brand products and share the GLP-1 side effect pattern; they are not FDA-approved finished products.
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and dispensed under a clinician's supervision. They are not FDA-approved finished drug products the way branded Ozempic, Wegovy, Mounjaro, or Zepbound are, and the FDA states it does not review them for safety, effectiveness or quality. As of May 31, 2026 the FDA had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide (FDA page current as of September 1, 2026). Their tolerability is expected to follow the same GLP-1 principles described above, but no trial has measured it, and we are not claiming a compounded product is identical to any branded drug.
What FormBlends actually offers
FormBlends offers medically supervised weight loss through compounded semaglutide and tirzepatide GLP-1 programs. It does not sell liraglutide, dulaglutide, orforglipron, or any brand-name GLP-1 product.
If tolerability is your main concern, the practical path is a clinician who can match the medication and titration pace to your sensitivity, not chasing a single "gentlest" brand. FormBlends provides that supervision for its semaglutide and tirzepatide programs, with dose escalation guided by how you respond. A clinician assessment determines eligibility, and compounded medications are dispensed only after that review.
Correction, September 2026: two drugs removed and label percentages added
As of September 5, 2026 this page has been re-checked against the current prescribing information for every marketed weight-management GLP-1 drug. Two changes matter. First, lixisenatide (Adlyxin) and exenatide (Byetta, Bydureon BCise) have been removed as options: Sanofi withdrew Adlyxin from the US market effective January 1, 2023, and AstraZeneca discontinued Byetta on October 25, 2024 and Bydureon BCise on October 28, 2024 (UnitedHealthcare provider notice, 2024). Second, the qualitative tolerability ratings have been replaced with the adverse-reaction percentages from the 2026 labels, which show that liraglutide at its 3 mg weight-management dose (Saxenda, nausea 39.3%) is not a low-nausea choice, contrary to what this page used to say.
What the 2025 network meta-analysis found (type 2 diabetes doses)
A Bayesian network meta-analysis published in Frontiers in Pharmacology in 2025 pooled 48 randomized trials with 27,729 participants, all with type 2 diabetes. Its rankings: tirzepatide had the highest probability of causing nausea (SUCRA 85.8, roughly 25% of participants) and diarrhea (SUCRA 92.2); dulaglutide had the lowest nausea and vomiting (SUCRA 26.4 for nausea, roughly 10%); lixisenatide ranked highest for vomiting (SUCRA 86.6) and lowest for diarrhea (15.1). Two caveats: these are diabetes doses, which are lower than weight-management doses for the same molecules, and lixisenatide is no longer available in the US. The analysis supports the general rule that potency and gastrointestinal effects rise together.
New oral option: Foundayo (orforglipron), approved 2026
Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist approved in 2026 (label revised 07/2026). Its label Table 1 reports, at 5.5, 9 and 17.2 mg versus placebo: nausea 26%, 34% and 35% versus 10%; constipation 20%, 27% and 24% versus 9%; diarrhea 21%, 23% and 25% versus 11%; vomiting 13%, 21% and 24% versus 4%; gastrointestinal adverse events overall 60% to 69% versus 37%. A July 2026 network meta-analysis in the BMJ (262 trials, 99,791 participants) placed orforglipron among the agents with the highest discontinuation for adverse events and estimated one-year weight loss of 9.9%, versus 14.9% for tirzepatide, 10.9% for oral semaglutide and 9.8% for injectable semaglutide. A pill avoids injections; it does not avoid the class side effects.
Frequently asked questions
Which GLP-1 has the least side effects?
No single one wins. On current labels the lowest nausea rates belong to the type 2 diabetes doses (Mounjaro 12 to 18%; dulaglutide about 10% in a 2025 network meta-analysis). Among weight-management drugs, Zepbound's 25 to 29% is the lowest and Wegovy's 44% the highest.
Which GLP-1 causes the least nausea?
At diabetes doses, dulaglutide ranked lowest in the 2025 network meta-analysis. At weight-loss doses, liraglutide (Saxenda) is not mild: its label reports 39.3% nausea. Lixisenatide is no longer sold in the US. Nausea is dose-dependent for all of them.
Which GLP-1 has the lowest discontinuation rate from side effects?
On the Zepbound label, discontinuation for adverse events in the main obesity trial was 4.3%, 7.1% and 6.2% on 5, 10 and 15 mg versus 2.6% on placebo. A July 2026 BMJ network meta-analysis of 262 trials found discontinuation for adverse events was highest with orforglipron, naltrexone-bupropion, liraglutide and phentermine-topiramate. Slow titration lowers discontinuation for every drug.
Do GLP-1 side effects go away over time?
Usually. Nausea and gastrointestinal symptoms tend to peak after starting or increasing the dose and ease within weeks as the body adapts.
Does the GLP-1 with the fewest side effects also give the most weight loss?
Rarely. The most potent agents tend to cause more side effects, so fewest side effects and most weight loss usually point to different drugs.
Are compounded GLP-1s easier to tolerate?
They follow the same GLP-1 tolerability rules. Compounded medications are not FDA-approved finished products, and titration still matters most.
What does FormBlends offer?
FormBlends offers clinician-supervised compounded semaglutide and tirzepatide for weight loss, with dose escalation matched to how you respond. This guide is informational.
Is Zepbound or Wegovy easier to tolerate?
On their current labels, Zepbound (revised 08/2026) reports nausea in 25 to 29% of participants, diarrhea in 19 to 23%, vomiting in 8 to 13% and constipation in 11 to 17%, while Wegovy 2.4 mg injection (revised 06/2026) reports nausea 44%, diarrhea 30%, vomiting 24% and constipation 24%. Those come from separate placebo-controlled trials, not a head-to-head tolerability study, but the gap is consistent across every category.
Is the oral GLP-1 pill gentler than the injections?
Not on the labels. Foundayo (orforglipron, 07/2026) reports nausea in 26 to 35% and vomiting in 13 to 24% of participants, and the Wegovy tablet carries the same class effects as the injection. A July 2026 BMJ network meta-analysis found orforglipron among the drugs with the highest discontinuation for adverse events. The tablet removes the needle, not the gastrointestinal side effects.
Are lixisenatide or exenatide still options in the US?
No. Sanofi stopped selling lixisenatide (Adlyxin) in the US as of January 1, 2023, and AstraZeneca discontinued Byetta on October 25, 2024 and Bydureon BCise on October 28, 2024 (UnitedHealthcare provider notice, 2024). Earlier versions of this page listed both as milder choices; that guidance is out of date and has been removed. Currently marketed GLP-1 drugs are semaglutide, tirzepatide, liraglutide, dulaglutide and orforglipron.
Related guides
- AOD-9604 Side Effects: What the Research Says About Safety and Tolerability
- GLP-1 Peptide Side Effects: What the Evidence Actually Shows | FormBlends
- Best GLP-1 for Heart Health: CV Outcomes Data Ranked
- Best GLP-1 for Sleep Apnea: Which Drug Improves OSA Most?
- GHRP-2 vs Ipamorelin: Side Effects, Dosing, and Which Works Better | FormBlends
- Hexarelin vs Ipamorelin: Side Effects, Potency, and Which to Choose | FormBlends
- Tool: side-effect checker
Sources
- US Pharmacist, GI adverse effects of GLP-1 receptor agonists: https://www.uspharmacist.com/article/gi-adverse-effects-of-glucagonlike-peptide1-receptor-agonists
- Comparative GI adverse effects of GLP-1 receptor agonists, network meta-analysis (2025), PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491879/
- FDA, compounding and 503A overview: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- GLP-1 receptor agonist class overview, prescribing information (FDA labels): https://www.accessdata.fda.gov/scripts/cder/daf/
- Novo Nordisk. Wegovy (semaglutide) prescribing information, revised 06/2026, section 6.1. https://www.novo-pi.com/wegovy.pdf
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026, section 6.1 Table 1 and section 14. https://pi.lilly.com/us/zepbound-uspi.pdf
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026, section 6.1 Table 1. https://pi.lilly.com/us/mounjaro-uspi.pdf
- Novo Nordisk. Saxenda (liraglutide) prescribing information, revised 02/2026, section 6.1. https://www.novo-pi.com/saxenda.pdf
- Eli Lilly and Company. Foundayo (orforglipron) prescribing information, revised 07/2026, section 6.1 Table 1. https://pi.lilly.com/us/foundayo-uspi.pdf
- Comparative gastrointestinal adverse effects of GLP-1 receptor agonists in type 2 diabetes: Bayesian network meta-analysis of 48 RCTs. Front Pharmacol 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12491879/
- Nong K et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ 2026;394:e372161, July 8, 2026. https://europepmc.org/article/MED/42419792
- UnitedHealthcare. Discontinuation of Bydureon BCise and Byetta, 2024. https://www.uhcprovider.com/en/resource-library/news/2024/discontinuation-bydureon-bcise-byetta.html
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of September 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →